Pressmeddelanden

LIPIGON PHARMACEUTICALS ANNOUNCES THE APPOINTMENT OF A NEW CHAIRMAN OF THE BOARD

Effective immediately Lipigon is announcing Dr. Gisela Sitbon as new Chairman of the Board. She is replacing Lars Öhman who will stay as member of the Board of Directors. Sitbon is currently Chairman of the Board at Beactica and stock exchange listed Nanologica. Lipigon is also welcoming Dr. Erik Lund as a new board member. Lund has more than 15 years of experience from the big pharma industry, most recently as director of business development at MSD.

"Bringing in these experienced external board members is an important step in the process of building a sustainable research based company. Gisela Sitbon has been involved in the life science industry at senior level for well over 25 years. She has vast experience from early stage companies and she has recently taken part in bringing two companies to the stock market. Erik Lund brings the sought after big pharma perspective to Lipigon and will play an important role in Lipigon's strategic development. These are two strong additions to the Board of Directors that I think complement the existing board very well." said CEO and Lipigon co-founder Stefan K Nilsson.

"I am honored to be nominated as new Chairman of the Board. Lipigon is an exciting company with a vision to make its mark within the field of lipid biology. They already achieved a research collaboration with AstraZeneca last year. I am looking forward to working with the Lipigon team and help them fine tune the strategy for the future." said Gisela Sitbon, new Chairman of the Board.

For further information, please contact:

Stefan K. Nilsson, CEO, Lipigon Pharmaceuticals
e-mail: stefan@lipigon.se
Tel: +46 70 578 17 68

About Lipigon

Lipigon is a spin out from Umeå University in Sweden. The company was founded by leading scientists in the field of cellular lipid transport. Lipigon is currently focusing on the discovery and development of novel treatments for dyslipidemia and metabolic diseases. For more information please visit: www.lipigon.se

2020-06-30

Lipigon Pharmaceuticals AB ("Lipigon") har framgångsrikt avslutat en
nyemission av aktier som tillför bolaget närmare 16,7 miljoner kronor. Kapitalet
ska primärt användas för att ta bolagets huvudprogram mot kliniska studier.

2020-06-30

Lipigon Pharmaceuticals has successfully closed a new share issue of nearly € 1,6 million. The capital raised will primarily be used to take the most advanced programme of the company towards clinical trials.

2020-05-14

Lipigon Pharmaceuticals AB ("Lipigon"), som utvecklar läkemedel mot
sjukdomar orsakade av rubbningar i kroppens hantering av fetter, tillkännager
idag att bolaget har ingått ett avtal med HitGen Inc. ("HitGen") som är noterat
på Shanghai-börsen. Bolagen kommer tillsammans att bedriva forskning för att
identifiera och utveckla läkemedelskandidater som påverkar enzymet LPL som
ansvarar för nedbrytning av blodfetter. Målet är att utveckla behandlingar av
hjärt-sjukdom och andra fettrelaterade sjukdomar.

2020-05-14

Lipigon enters agreement with HitGen to develop drugs for cardiometabolic diseases Lipigon Pharmaceuticals AB ("Lipigon"), developer of therapeutics for lipid-related diseases, today announced that the company has entered an agreement with STAR listed (Shanghai market) company HitGen Inc. ("HitGen"). The companies will conduct joint research to identify and develop drug candidates that enhance the activity of Lipoprotein Lipase (LPL), with the aim to be used in treatment of lipid disorders and cardiovascular disease.

2020-03-23

Lipigon Pharmaceuticals ("Lipigon") tillkännagav idag att bolaget har förvärvat en RNA-läkemedelskandidat baserad på antisens-teknologin som tagits fram med Secarna Pharmceuticals ("Secarna") inom ramen för ett tidigare forskningssamarbete. Lipgion kommer att bedriva fortsatt forskning och utveckling av de förvärvade tillgångarna som inriktar sig på ANGPTL, en genfamilj som bland annat står för reglering av blodfetter. Secarna kommer att erhålla marknadsmässiga betalningar för transaktionen. Parterna har valt att inte offentliggöra närmare detaljer om ersättningen.

2020-03-23

Lipigon acquires antisense drug candidates for cardiovascular and metabolic diseases from Secarna Lipigon Pharmaceuticals ("Lipigon") announced that the company has acquired antisense drug candidates jointly generated with Secarna Pharmaceuticals ("Secarna") under a previous research collaboration. Lipigon will continue the research and development of the acquired assets targeting the ANGPTL gene family, and Secarna will receive undisclosed payments customary for such a transaction.

2019-10-10

Lipigon Pharmaceuticals ("Lipigon") tillkännager att bolaget har ingått ett avtal om samarbete och utlicensiering med CombiGene AB (publ) ("CombiGene") avseende utveckling av en avancerad genterapi för behandling av den sällsynta sjukdomen lipodystrofi. Lipigon och CombiGene kommer inom ramen för avtalet att samarbeta under projektets tidiga utvecklingsfaser.

2017-12-09

Lipigons VD Dr. Stefan K Nilsson väljs in i The European Lipoprotein Club (ELC), det äldsta och mest aktiva europeiska nätverket inom lipidfältet. ELC etablerades 1977 för att främja samarbete och utbyte av idéer inom grundforskning och klinisk forskning på lipoproteiner (blodfettskomplex).

2017-10-10

Lipigon Pharmaceuticals ("Lipigon") tillkännagav idag att bolaget har tecknat avtal avseende validering av målprotein för läkemedelsutveckling med Secarna Pharmaceuticals ("Secarna") som är specialiserat på RNA-behandlingar genom s.k. antisens-teknologi. Målet är att tillsammans utveckla ett läkemedel som är best-in-class för behandling av allvarliga former av dyslipidemi (allmänna blodfettsrubbningar) och närliggande sjukdomar.

2017-10-10

Lipigon Pharmaceuticals ("Lipigon") announced today that it has entered into a Target Validation Research Agreement with Munich-based antisense therapeutics company Secarna Pharmaceuticals ("Secarna"). The goal is to co-develop a best-in-class drug for treatment of severe forms of dyslipidemia and related lipid disorder driven diseases.

2016-12-26

Starting December 2016 Lipigon joins the AZ BioVentureHub located at AstraZeneca's site in Mölndal, Sweden. The contract stretches over 1 year giving Lipigon an office and full access to the whole facility, including infrastructure and capabilities.

2016-12-01

Lipigon is happy to announce 3 new major partners investing in the company. Umeå based Fort Knox Förvaltning AB (Owner of Balticgruppen) and Partnerinvest Övre Norrland AB together with Antaros Medical AB in Gothenburg have entered as new shareholders. The investments allow for Lipigon to expand within present programs and to evaluate novel targets.

<<
1
...
10
11
12
13
>>

Nyheter

27 januari, 2023, Pressmeddelande

Lipigon tar sikte på fas II

Under den senaste tiden har Lipigon kommit med flera positiva nyheter om bolagets blodfettssänkande ...

23 januari, 2023, Pressmeddelande

Lipigons vd Stefan K. Nilsson ökar sitt innehav i bolaget

Lipigon Pharmaceuticals AB ("Lipigon") meddelar i dag att vd Stefan K. Nilsson har köpt aktier i Lip...

19 januari, 2023, Pressmeddelande

Lipigon rapporterar ytterligare positiva data från fas I-studie med Lipisense

Lipigon Pharmaceuticals AB ("Lipigon") tillkännagav i dag positiva säkerhetsresultat från fas I-stud...